Access cutting-edge head and neck cancer treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.
Access head and neck cancer specialists in Kansas City at no cost
This study follows strict safety protocols and ethical guidelines
All study-related head and neck cancer treatment provided free
This multicenter, open-label, randomized phase 3 trial will determine if palbociclib and cetuximab (Arm 1) improves overall survival (OS) in comparison to cetuximab monotherapy (Arm 2) in patients with CDKN2A-altered, HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on a PD-1/L1 inhibitor (given as monotherapy or in combination with other therapy).
Sponsor: Washington University School of Medicine
Check if you qualify for this head and neck cancer clinical trial in Kansas City, MO
If you're searching for head and neck cancer treatment options in Kansas City, MO, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced head and neck cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.